180 related articles for article (PubMed ID: 30096175)
1. Contribution of excision repair cross-complementing group 1 genotypes to triple negative breast cancer risk.
Tsai CW; Chang WS; Shen TC; Su CH; Wang HC; Liu LC; Bau DT
PLoS One; 2018; 13(8):e0202112. PubMed ID: 30096175
[TBL] [Abstract][Full Text] [Related]
2. The Contribution of Excision Repair Cross-complementing Group 1 Genotypes to Colorectal Cancer Susceptibility in Taiwan.
Yueh TC; Chou AK; Gong CL; Fu CK; Pei JS; Wu MH; Tsai CW; Chang WS; Hsiao CL; Yen ST; Li HT; Bau DT
Anticancer Res; 2017 May; 37(5):2307-2313. PubMed ID: 28476796
[TBL] [Abstract][Full Text] [Related]
3. The Significant Interaction of Excision Repair Cross-complementing Group 1 Genotypes and Smoking to Lung Cancer Risk.
Chen LH; Shen TC; Li CH; Chiu KL; Hsiau YC; Wang YC; Gong CL; Wang ZH; Chang WS; Tsai CW; Hsia TC; Bau DT
Cancer Genomics Proteomics; 2020; 17(5):571-577. PubMed ID: 32859635
[TBL] [Abstract][Full Text] [Related]
4. [Polymorphisms of ERCC1 gene and outcomes in epithelial ovarian cancer patients with platinum-based chemotherapy].
Qi BL; Li Y; Wang N; Zhou RM; Hu P; Kang S
Zhonghua Fu Chan Ke Za Zhi; 2013 Nov; 48(11):847-52. PubMed ID: 24444563
[TBL] [Abstract][Full Text] [Related]
5. Role of common ERCC1 polymorphisms in cisplatin-resistant epithelial ovarian cancer patients: A study in Chinese cohort.
Bao Y; Yang B; Zhao J; Shen S; Gao J
Int J Immunogenet; 2020 Oct; 47(5):443-453. PubMed ID: 32173978
[TBL] [Abstract][Full Text] [Related]
6. Contribution of DNA Double-strand Break Repair Gene XRCC3 Genotypes to Triple-negative Breast Cancer Risk.
Su CH; Chang WS; Hu PS; Hsiao CL; Ji HX; Liao CH; Yueh TC; Chuang CL; Tsai CW; Hsu CM; Lane HY; Bau DT
Cancer Genomics Proteomics; 2015; 12(6):359-67. PubMed ID: 26543082
[TBL] [Abstract][Full Text] [Related]
7. Prognostic value of ERCC1 and ERCC2 gene polymorphisms in patients with gastric cancer receiving platinum-based chemotherapy.
Mo J; Luo M; Cui J; Zhou S
Int J Clin Exp Pathol; 2015; 8(11):15065-71. PubMed ID: 26823845
[TBL] [Abstract][Full Text] [Related]
8. Association of ERCC1 polymorphisms (rs3212986 and rs11615) with the risk of head and neck carcinomas based on case-control studies.
Ding YW; Gao X; Ye DX; Liu W; Wu L; Sun HY
Clin Transl Oncol; 2015 Sep; 17(9):710-9. PubMed ID: 26022132
[TBL] [Abstract][Full Text] [Related]
9. Effect of ERCC1 polymorphism on the response to chemotherapy and clinical outcome of non-small cell lung cancer.
Gao H; Ge RC; Liu HY; Wang Y; Yan S
Genet Mol Res; 2014 Oct; 13(4):8997-9004. PubMed ID: 25366790
[TBL] [Abstract][Full Text] [Related]
10. Polymorphisms in the ERCC1 and XPF genes and risk of breast cancer in a Chinese population.
Yang Z; Fang X; Pei X; Li H
Genet Test Mol Biomarkers; 2013 Sep; 17(9):700-6. PubMed ID: 23909490
[TBL] [Abstract][Full Text] [Related]
11. Study on the ERCC1 gene polymorphism response to chemotherapy and prognosis of gastric cancer.
Liu L; Li CH; Jin TF; Xu DY
Genet Mol Res; 2014 Oct; 13(4):8722-8. PubMed ID: 25366763
[TBL] [Abstract][Full Text] [Related]
12. The effect of ERCC1 and ERCC2 gene polymorphysims on response to cisplatin based therapy in osteosarcoma patients.
Obiedat H; Alrabadi N; Sultan E; Al Shatti M; Zihlif M
BMC Med Genet; 2018 Jul; 19(1):112. PubMed ID: 29980176
[TBL] [Abstract][Full Text] [Related]
13. Genetic polymorphisms in nucleotide excision repair pathway influences response to chemotherapy and overall survival in osteosarcoma.
Sun Y; Wu Y; Li W; Kong Z; Zou X
Int J Clin Exp Pathol; 2015; 8(7):7905-12. PubMed ID: 26339355
[TBL] [Abstract][Full Text] [Related]
14. DNA repair genes XRCC1 and ERCC1 polymorphisms and the risk of sporadic breast cancer in Han women in the Gansu Province of China.
Zhu G; Wang L; Guo H; Lu L; Yang S; Wang T; Guo H; Wang H; Min J; Yang K; Chen X; Liu Y; Wang Z; Su H
Genet Test Mol Biomarkers; 2015 Jul; 19(7):387-93. PubMed ID: 25961110
[TBL] [Abstract][Full Text] [Related]
15. Genetic variability of genes in NER pathway influences the treatment outcome of gastric cancer.
Xue MH; Li GY; Wu XJ; Zhang CX; Zhang CF; Zhu KX
Int J Clin Exp Pathol; 2015; 8(5):5563-9. PubMed ID: 26191265
[TBL] [Abstract][Full Text] [Related]
16. Genetic variability of DNA repair mechanisms influences chemotherapy outcome of gastric cancer.
Yu H; Wu X; Zhang Y; Jin Z; Li G; Zhao H
Int J Clin Exp Pathol; 2015; 8(4):4106-12. PubMed ID: 26097599
[TBL] [Abstract][Full Text] [Related]
17. The determination of relationship between "excision repair cross-complementing group 1" (ERCC1) gene T19007C and C8092A single nucleotide polymorphisms and clinicopathological parameters in non-small cell lung cancer.
Koç E; Caner V; Büyükpınarbaşılı N; Tepeli E; Türk NS; Ozan Çetin G; Bağcı G
Mol Biol Rep; 2012 Jan; 39(1):375-80. PubMed ID: 21553053
[TBL] [Abstract][Full Text] [Related]
18. Influence of ERCC1 and ERCC4 polymorphisms on response to prognosis in gastric cancer treated with FOLFOX-based chemotherapy.
Lu ZM; Luo TH; Nie MM; Fang GE; Ma LY; Xue XC; Wei G; Ke CW; Bi JW
Tumour Biol; 2014 Apr; 35(4):2941-8. PubMed ID: 24318989
[TBL] [Abstract][Full Text] [Related]
19. Neoadjuvant radiochemotherapy in adenocarcinoma of the esophagus: ERCC1 gene polymorphisms for prediction of response and prognosis.
Metzger R; Warnecke-Eberz U; Alakus H; Kütting F; Brabender J; Vallböhmer D; Grimminger PP; Mönig SP; Drebber U; Hölscher AH; Bollschweiler E
J Gastrointest Surg; 2012 Jan; 16(1):26-34; discussion 34. PubMed ID: 21956434
[TBL] [Abstract][Full Text] [Related]
20.
Li B; Shi X; Yuan Y; Peng M; Jin H; Qin D
Biosci Rep; 2018 Jun; 38(3):. PubMed ID: 29752341
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
